Navigation Links
ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
Date:2/20/2008

HALIFAX, Feb. 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, announced today the appointment of former senator, Michael Kirby, as the new Board of Directors Chair. Michael Kirby succeeds the late Dr. Warrick Kimmins, who provided exemplary leadership during his tenure and was instrumental in spinning out IVT's novel technology from Dalhousie University.

"I am passionate about advancing health care and am delighted to be part of such a fast-growing biotech company," said former senator Michael Kirby. "IVT has an impressive track record and its patented technology holds tremendous potential to improve vaccines worldwide. "

"Michael Kirby is an internationally respected leader in health care," said Dr. Randal Chase, IVT President and CEO. "His strategic advice will be invaluable, as we enter the next phase of development with the expectation of beginning a new Phase 1 clinical trial in 2009."

The Honourable Michael Kirby has had a distinguished career spanning academia, business, provincial, and federal public service. Most recently, he was appointed, by Prime Minister Stephen Harper, to be the first Chair of the Mental Health Commission of Canada. He also serves on several boards including The Bank of Nova Scotia, Extendicare, Ontario Energy Savings Income Trust, MDC Partners, and Indigo Books and Music.

Senator Kirby was past chair of the Standing Senate Committee on Social Affairs, Science and Technology. He has been a member of the Trilateral Commission, the Council of the International Institute for Applied Systems Analysis, Luxemburg, Austria, and the Club of Rome. He was also a full-time professor in the School of Business Administration and the School of Public Administration at Dalhousie University.

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT cre
'/>"/>

SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
3. NASA MidSTAR-1 successful technologies may be revolutionary
4. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
5. Neurobiological Technologies Sets Date for Research and Development Day
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
7. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
8. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
9. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
10. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , PLYMOUTH, Mass., Dec. 1 /PRNewswire/ ...m ) announced today results from the company spons...machandra Medical Center in Chennai, India using t...n-reconstructable Critical Limb Ischemia (CLI). Sr...international-associated institution based in Chen...
(Date:12/1/2009)..., , SPRINGFIELD, Ill., Dec. 1 /PRNewsw..., is proud to announce that it was recently awarde... Awards event on Nov. 13 in New York City. The CLI... and innovation in the healthcare advertising indu...f the world,s most recognized awards competitions ...
(Date:12/1/2009)..., , CRANBURY, N.J., Dec. 1 /PRNewswire-Fi... PTN ) today announced that the U.S. Patent and T...40, titled "Cyclic Natriuretic Peptide Constructs....of cyclic compounds that bind to natriuretic pepti... lead heart failure drug candidate. ,, "Our nat...
(Date:12/1/2009)..., , SAN FRANCISCO, Dec. 1 /PRNewswire-Fi...etin Board: MZEI) announced today that in tests in..., it continues to break "6 log" decontamination ba...rming bacteria, Claustridium difficile and Bacilli...cSure(TM) as an extremely potent sporicidal techno...
Breaking Biology Technology:Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2
... 2009 Senomyx, Inc. (Nasdaq: SNMX ) will releas... fiscal year ending December 31, 2008 on Thursday,...financial markets. The Company will also host a c...0 a.m. Eastern Time (8:00 a.m. Pacific Time) that ...ill provide a business update and will discuss the...
...o help eye specialists better understand the impac...eir patients, Viscira teamed up with an industry-l...a virtual experience of having neovascular (wet) a... San Francisco, CA (PRWEB) January ...and the impact of one of the fastest growing eye d...
...exsun Corp, a leader in renewable energy and biofu...e appointment of David Pyrce as its Chief Executiv... Los Angeles (PRWEB) Janua...energy and biofuels development and production, to...s Chief Executive Officer and member of the Board ...
Other Biology Technology:SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 2Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 3Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer 2
(Date:12/1/2009)...unce the publication of results from its Phase II ...rability of its novel, intranasal drug/device prod...sitis with nasal polyps in Rhinology , the offici...logic Societies. , Chronic rhinosinusitis with ...cantly reduce a patient,s quality of life, causing...
(Date:12/1/2009)...researchers have developed a tumor-attacking viru... growth of new tumor blood vessels. , Their rese...lls oncolytic viruses might be more effective ag... gene for a protein that inhibits blood-vessel gro...ally produced in the brain. In this study, an onco...
(Date:12/1/2009)...rks can be solved with a new technique that identi...their victims, according to a University of Florid...logous to analyzing human fingerprints, scientists...hark bites to the jaws and teeth of the powerful p...ernational Shark Attack File, which is housed at U...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Caraco Pharmaceutical Laboratories Ltd Markets Nicardipine Hydrochloride Injection 6376 1Caraco Pharmaceutical Laboratories Ltd Markets Nicardipine Hydrochloride Injection 6376 2Cancers sweet tooth may be weakness 10788 1Cancers sweet tooth may be weakness 10788 2HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 1HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 2
... Conn. A joint Yale-Peking University center that...erstanding of plant biology will receive five year...nto Company, a leading provider of agricultural te...es and a series of plant biology-related programs ...olecular Genetics and Agrobiotechnology , a multid...
...computers to compare portions of the human genome ...l have discovered some 300 previously unidentified...red genes already known., The discovery is based o...enetic code that do something useful for the organ...orted by Adam Siepel, Cornell assistant professor ...
...rne diseases such as malaria and dengue cause suff...auses at least one million deaths annually, and is...e of five. In addition to the human toll, these d...y communities that can least afford it. Various a...secticides, vaccine development, and preventive me...
Other Biology News:Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2Evolutionary comparison finds new human genes 2Evolutionary comparison finds new human genes 3Selfish DNA and the Genetic Control of Vector-Borne Diseases 2Selfish DNA and the Genetic Control of Vector-Borne Diseases 3
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Goat Anti-SPFH2 Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Als2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Biology Products: